51st Annual Meeting of the EBMT congress coverage: Lymphoma (Part 2)

Stay up to date with the latest developments in lymphoma (Part 2) with our live social media coverage from the 51st Annual Meeting of the EBMT, March 30 –April 2, 2025, Florence, Italy.  

CONGRESS | #EBMT25 | PRESENTATION
Charalampia Kyriakou from @uclh discussed results from the study on stem cell transplantation for Waldenstrom’s Macroglobulinemia conducted by the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
ASCT in… pic.twitter.com/j4vBd96t2q

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | PRESENTATION
Bertram Glass @BuchHelios presented on ctDNA as an early outcome predictor in second-line LBCL after liso-cel vs SOC. Significantly more patients achieved undetectable ctDNA with liso-cel (62%) compared to SOC (38%). In the liso-cel arm,… pic.twitter.com/8OgSpBdlOj

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | PRESENTATION
Ali Bazarbachi @AUBMC_Official discusses the importance of allo-HCT in Hodgkin #lymphoma.
Follow our live feed for more updates: https://t.co/fJoKaNsrCt#lymphoma #lymsm #MedicalCongress @TheEBMT pic.twitter.com/Q2monJluFy

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | PRESENTATION
Philipp Berning @UK_Muenster discussed the role of allotransplant in T-cell #lymphoma focusing on the timing of allo-HCT, how to improve outcomes, and the impact of histology on transplant outcomes.
Follow our live feed for more updates:… pic.twitter.com/2F20cArqRj

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | PRESENTATION @DrBastosOreiroM, Gregorio Marañón Hospital provides an overview of CAR T-cell therapies in #lymphoma by sharing the clinical and real-world data in patients with DLBCL, FL, and MCL.
Follow our live feed for more updates:… pic.twitter.com/LUCsEdNj3e

— Lymphoma Hub (@lymphomahub) April 1, 2025

CONGRESS | #EBMT25 | POSTER
Jia Wei, Tongji Hospital, China presents interim findings from a phase I/II trial of CD19/20 CAR T-cell therapy in patients with relapsed/refractory B-cell lymphoma (N = 51). At 3 months, best ORR = 84% and CR = 52%. Patients treated with autologous… pic.twitter.com/DCHQ2HRvPY

— Lymphoma Hub (@lymphomahub) March 31, 2025

CONGRESS | #EBMT25 | POSTER
Gabriele Facchin, University Hospital, Azienda sanitaria universitaria Friuli Centrale, Italy shares findings from a retrospective study in patients with relapsed/refractory lymphoma (N = 6) treated with bispecific antibodies followed by allogeneic… pic.twitter.com/ZFGBBhGPYj

— Lymphoma Hub (@lymphomahub) March 31, 2025

CONGRESS | #EBMT25 @theEBMT | PRESENTATION @GunjanLShah @uclh presented the initial results from the phase II LUMINICE-203 study of acimtamig combined with off-the-shelf allogeneic natural killer cells (AB-101) in patients with R/R classical Hodgkin #lymphoma.
N=22, ORR=86%,… pic.twitter.com/6q6QAD9kjM

— Lymphoma Hub (@lymphomahub) March 31, 2025

CONGRESS | #EBMT25 @theEBMT | PRESENTATION
Charalampia Kyriakou from @uclh discussed classification of lymphomas in the EBMT registry based on the 5th edition of the World Health Organization's classification of haematolymphoid tumors. Follow our live feed for more updates:… pic.twitter.com/fBowGkW26u

— Lymphoma Hub (@lymphomahub) March 31, 2025

CONGRESS | #EBMT25 @theEBMT | PRESENTATION @corradini_paolo, University of Milano, discusses the role of liquid biopsy in T-cell directing treatments for lymphomas by sharing an overview of general concepts on liquid biopsy, cell free DNA, ctDNA. Importance of molecular… pic.twitter.com/PWcDuq2ddF

— Lymphoma Hub (@lymphomahub) March 31, 2025